MICROBOT MEDICAL INC. - COMMON STOCK

Microbot Medical Closes $13 Million Registered Direct Offering

11 Feb 2025 17:15:48 By Nasdaq GlobeNewswire

Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

10 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting

04 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

21 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Closes $8.6 Million Registered Direct Offering

10 Jan 2025 09:25:51 By Nasdaq GlobeNewswire

Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility

07 Jan 2025 15:15:00 By Nasdaq GlobeNewswire

Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®

30 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access

10 Dec 2024 09:18:37 By Nasdaq GlobeNewswire

Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

15 Oct 2024 07:38:00 By Nasdaq GlobeNewswire

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

30 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

22 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

13 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

18 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

09 Jul 2024 07:30:00 By Nasdaq GlobeNewswire